MedTrace Logo

The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism

NCT01087879 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2011-09-07

No results posted yet for this study

Summary

The impact of different administration routes of hormonal contraceptives on androgen secretion, glucose metabolism and inflammation. A prospective randomized trial.

The investigators assume, that transdermal or transvaginal hormonal contraception would have less effects on androgen levels, glucose metabolism and inflammatory markers than oral contraceptives.

Conditions

  • Contraception

Interventions

DRUG

Desogestrel-Ethinyl Estradiol contraceptive pill

150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.

DRUG

Etonogestrel-Ethinyl Estradiol vaginal ring

Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.

DRUG

Norelgestromin-Ethinyl Estradiol contraceptive patch

A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.

Sponsors & Collaborators

  • University of Oulu

    lead OTHER

Principal Investigators

  • Juha S. Tapanainen, Professor · Dept Ob-Gyn, University of Oulu

  • Terhi T. Piltonen, MD · Dept Ob-Gyn, University of Oulu

  • Johanna M. Puurunen, MD · Dept Ob-Gyn, Univeristy of Oulu

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01087879 on ClinicalTrials.gov